Emcure Pharmaceuticals DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.73×0.73×0.73×
0.89×0.89×0.89×
16.1%15.7%13.8%
1.03×1.03×0.96×
1.93×1.93×1.77×
20.9%20.3%15.3%
19.7%19.7%15.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EMCURE₹1,865.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹35,359 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.730.730.73
Interest Burden (Pretax/EBIT) ×0.890.890.89
EBIT Margin %13.8115.7516.06
Asset Turnover ×0.961.031.03
Financial Leverage (Assets/Equity) ×1.771.931.93
ROE (5-step product, year-end total equity) %15.2620.3520.93
ROE (owners' profit / average owners' equity) %15.3219.6819.68
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.